AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...

Japan and China said Friday they have reached a deal toward resolving their disputes over the discharge of treated radioactive wastewater from the tsunami-hit Fukushima Daiichi nuclear power plant int ...

Daiichi Sankyo and AstraZeneca saw a dip in stock prices after announcing that their Phase III TROPION-Breast01 trial for ...

IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...

The IAEA supports China and Japan's agreement to resume seafood imports from Japan after verifying the Fukushima water ...

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

The experimental precision drug, developed with Japan's Daiichi Sankyo, did not significantly improve overall survival rates ...

Chinese top diplomat Wang Yi (right) meets with Japanese Foreign Minister Yoko Kamikawa in New York on September 23, 2024.

Discover Daiichi Sankyo's groundbreaking patent for monoclonal antibodies targeting LAG-3, offering new hope for treating autoimmune diseases with enhanced efficacy.

It is a fictional representation created for illustrative purposes only. AstraZeneca's experimental precision drug, developed ...

First, reaching this agreement means neither China has changed its opposition to discharging nuclear-contaminated water into ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...